ORGANOGENESIS HOLDINGS INC. (ORGO) Operating Margin
- Operating margin · 12 months: Value -7.84%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -7.84% | Operating income / revenue. Period ending 2026-06-30. $-35.87M ÷ $457.45M × 100 ≈ -7.84% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -35.87M USD | Operating Income (Loss) |
| Revenue | 457.45M USD | |
| Cost of products and services | (m) | |
| Research and development | 56.97M USD | Research and Development Expense |
| Selling, general and administration | 299.07M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-35.87M | $457.45M | (m) | $56.97M | $299.07M | -7.84% |
| 2026-03-31 | $2.55M | $514.70M | (m) | $49.06M | $318.91M | 0.50% |
| 2025-12-31 | $44.69M | $564.17M | (m) | $44.54M | $326.24M | 7.92% |
| 2025-09-30 | $-8.38M | $465.22M | (m) | $45.79M | $299.92M | -1.80% |
| 2025-06-30 | $-22.86M | $429.53M | (m) | $42.91M | $291.97M | -5.32% |
| 2025-03-31 | $-24.18M | $458.76M | (m) | $48.10M | $294.70M | -5.27% |
| 2024-12-31 | $-1.28M | $482.04M | (m) | $50.27M | $294.51M | -0.27% |
| 2024-09-30 | $-12.77M | $455.04M | (m) | $50.51M | $282.04M | -2.81% |
| 2024-06-30 | $-10.96M | $448.39M | (m) | $50.64M | $274.46M | -2.44% |
| 2024-03-31 | $12.67M | $435.47M | (m) | $45.99M | $268.24M | 2.91% |
| 2023-12-31 | $12.53M | $433.14M | (m) | $44.38M | $269.75M | 2.89% |
| 2023-09-30 | $22.51M | $449.00M | (m) | $44.01M | $276.67M | 5.01% |
| 2023-06-30 | $16.24M | $457.33M | (m) | $43.11M | $291.77M | 3.55% |
| 2023-03-31 | $18.43M | $461.42M | (m) | $42.38M | $294.06M | 3.99% |
| 2022-12-31 | $22.30M | $450.89M | (m) | $39.76M | $283.81M | 4.95% |
| 2022-09-30 | $33.34M | $463.24M | (m) | $36.63M | $282.76M | 7.20% |
| 2022-06-30 | $47.82M | $460.13M | (m) | $36.01M | $265.81M | 10.39% |
| 2022-03-31 | $61.17M | $463.62M | (m) | $33.12M | $255.55M | 13.19% |
| 2021-12-31 | $72.92M | $468.06M | (m) | $30.74M | $250.20M | 15.58% |
| 2021-09-30 | $74.77M | $446.31M | (m) | $28.78M | $235.63M | 16.75% |
| 2021-06-30 | $80.95M | $433.35M | (m) | $23.54M | $224.94M | 18.68% |
| 2021-03-31 | $55.12M | $379.12M | (m) | $20.89M | $209.10M | 14.54% |
| 2020-12-31 | $27.41M | $338.30M | (m) | $20.09M | $203.48M | 8.10% |
| 2020-09-30 | $3.89M | $306.14M | (m) | $17.43M | $202.63M | 1.27% |
| 2020-06-30 | $-27.36M | $269.60M | (m) | $17.64M | $200.96M | -10.15% |
| 2020-03-31 | $-32.42M | $265.59M | (m) | $16.84M | $203.41M | -12.21% |
| 2019-12-31 | $-29.46M | $260.98M | (m) | $14.80M | $199.69M | -11.29% |
| 2019-09-30 | $-32.19M | (m) | (m) | $14.25M | $194.80M | (m) |
| 2019-06-30 | $-33.99M | (m) | (m) | $13.11M | $183.91M | (m) |
| 2019-03-31 | $-43.70M | (m) | (m) | $11.29M | $172.69M | (m) |
| 2018-12-31 | $-51.56M | $193.45M | (m) | $10.74M | $161.96M | -26.65% |
| 2018-09-30 | $-5.65M | $0.00 | (m) | (m) | (m) | (m) |
| 2018-06-30 | $-6.25M | $0.00 | (m) | (m) | (m) | (m) |
| 2018-03-31 | $-5.53M | $0.00 | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-4.59M | $0.00 | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |